公开(公告)号：EP3364973A1

公开(公告)日：2018-08-29

申请号：EP16794470.1

申请日：2016-10-24

申请人： The Jackson Laboratory

发明人： JOHN, Simon, W.M. ,  WILLIAMS, Peter, Alexander

IPC分类号： A61K31/455 ,  A61K31/465 ,  A61K31/19 ,  A61K48/00 ,  C12N15/86 ,  A61P27/02 ,  A61P27/06 ,  A61K45/06

CPC分类号： A61K31/455 ,  A61K31/19 ,  A61K31/4745 ,  A61K31/706 ,  A61K38/00 ,  A61K38/45 ,  A61K45/06 ,  A61K48/005 ,  A61P27/06 ,  C12N2750/14143 ,  C12Y207/07001 ,  A61K2300/00

摘要： The invention relates to the use of a pharmaceutical composition containing nicotinamide (NAM) and/or pyruvate as a neuroprotective medicament or gene therapy in the treatment of neurodegenerative disorders, in particular axon degeneration of neuronal tissue in ocular-related neurodegeneration diseases including glaucoma.

公开(公告)号：EP2979695B1

公开(公告)日：2018-08-01

申请号：EP14775889.0

申请日：2014-03-31

申请人： AskAt Inc.

发明人： OKUMURA, Takako ,  KOIZUMI, Shinichi ,  HARA, Hideaki

IPC分类号： A61K31/352 ,  A61P9/00 ,  A61P27/02 ,  A61P27/06 ,  A61K31/382 ,  C07D311/58

CPC分类号： A61K31/352 ,  A61K31/382 ,  C07D311/58

摘要： {Summary of the invention} The purpose of this invention is to provide a compound for preventing or treating an ocular disease and a pharmaceutical composition comprising the same. This invention provides a pharmaceutical composition comprising a compound as defined by the formula (I') or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is useful for preventing or treating an ocular disease such as retinochoroidal degeneration.

公开(公告)号：EP3345622A1

公开(公告)日：2018-07-11

申请号：EP16841886.1

申请日：2016-08-31

申请人： Kowa Company, Ltd.

发明人： KAWAMATA, Kenji ,  MARUO, Kazushi ,  SUGANAMI, Hideki

IPC分类号： A61K45/00 ,  A61K31/551 ,  A61P27/02 ,  A61P27/06 ,  A61P43/00

CPC分类号： A61K31/551 ,  A61K45/00 ,  A61P27/06

摘要： The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period of time, said drug comprising an Rho kinase inhibitor, more specifically, to a therapeutic agent comprising an Rho kinase inhibitor for treating glaucoma or ocular hypertension in a patient suffering from glaucoma or ocular hypertension who has been administered with a therapeutic agent comprising the Rho kinase inhibitor for treating glaucoma or ocular hypertension continuously over a definite period of time and needs a further enhanced ocular hypotensive effect.

公开(公告)号：EP3238746A4

公开(公告)日：2018-06-27

申请号：EP15873258

申请日：2015-12-25

申请人： UNIV KYOTO

发明人： SUDA KENJI ,  MURAKAMI TATSUYA ,  YOSHIMURA NAGAHISA ,  GOTOH NORIMOTO

IPC分类号： A61K47/42 ,  A61K9/08 ,  A61K9/127 ,  A61K45/00 ,  A61K47/24 ,  A61P3/10 ,  A61P9/10 ,  A61P27/02 ,  A61P27/06 ,  A61P27/10 ,  A61P27/12 ,  A61P29/00

CPC分类号： A61K47/64 ,  A61K9/0048 ,  A61K31/506 ,  A61K45/00 ,  A61K47/24 ,  A61K47/42 ,  A61K47/6455 ,  A61K47/6917

摘要： The purpose of the present invention is to provide a novel system for the delivery of a drug to a posterior segment of the eye. The present invention relates to: a cytophilic peptide-fused high-density lipoprotein (cHDL) which can be used as a carrier for the delivery of a drug to a posterior segment of the eye; a method for producing the cytophilic peptide-fused high-density lipoprotein; a system of the delivery of a drug to a posterior segment of the eye, a pharmaceutical composition, and a system of the delivery of a drug to a posterior segment of the eye, each of which utilizes the cytophilic peptide-fused high-density lipoprotein; and a method for diagnosing, preventing or treating posterior ocular disease.

公开(公告)号：EP3231438A4

公开(公告)日：2018-06-20

申请号：EP15867628

申请日：2015-12-10

申请人： INT INSTITUTE OF CANCER IMMUNOLOGY INC

发明人： SUGIYAMA HARUO

IPC分类号： A61K38/17 ,  A61K9/00 ,  A61K35/17 ,  A61K39/00 ,  A61P27/02 ,  A61P27/06 ,  A61P35/00 ,  C07K7/06 ,  C07K14/47

CPC分类号： A61K38/02 ,  A61K9/0019 ,  A61K9/006 ,  A61K35/17 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/00 ,  A61K39/0011 ,  A61P27/02 ,  C07K7/04 ,  C07K7/06 ,  C07K14/4748

摘要： The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.

公开(公告)号：EP3321259A1

公开(公告)日：2018-05-16

申请号：EP16820624.1

申请日：2016-07-04

申请人： Guangzhou Magpie Pharmaceutical Co., Ltd.

发明人： WANG, Yuqiang ,  YU, Pei ,  SUN, Yewei ,  SHAN, Luchen ,  ZHANG, Gaoxiao ,  ZHANG, Zaijun ,  YI, Peng

IPC分类号： C07D241/12 ,  A61K31/497 ,  A61P9/00 ,  A61P9/10 ,  A61P7/02 ,  A61P11/00 ,  A61P25/28 ,  A61P25/16 ,  A61P25/14 ,  A61P21/00 ,  A61P21/04 ,  A61P27/06

CPC分类号： A61K31/497 ,  C07D241/12

摘要： The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and treatment of cardiovascular and cerebrovascular diseases, neurodegenerative diseases and other related diseases.

摘要翻译： 吡嗪衍生物及其制备方法和医学用途技术领域本发明涉及吡嗪衍生物， 该吡嗪衍生物可以去除自由基，抑制钙超载，具有细胞保护作用，可用于心脑血管疾病，神经退行性疾病等相关疾病的防治。

公开(公告)号：EP3050563B1

公开(公告)日：2018-05-09

申请号：EP16161920.0

申请日：2011-09-16

申请人： ALLERGAN, INC.

发明人： Dibas, Mohammed I. ,  Chow, Ken ,  Donello, John E. ,  Garst, Michael E. ,  Gil, Daniel W. ,  Wang, Liming

IPC分类号： A61K31/4174 ,  A61P27/06

CPC分类号： A61K31/4174 ,  A61K9/0014 ,  A61K31/4164 ,  C07D233/64 ,  Y10S514/912

摘要： The present invention relates to novel compounds, ester pro-drugs of [3-(1-(1 H -imidazol-4-yl)ethyl)-2-methylphenyl] methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.

公开(公告)号：EP3305073A1

公开(公告)日：2018-04-11

申请号：EP17187452.2

申请日：2010-12-15

申请人： Samumed, LLC

发明人： HOOD, John ,  KC, Sunil Kumar ,  WALLACE, David Mark

IPC分类号： A01N43/52 ,  A01N43/56 ,  A61K31/415 ,  C07D471/04 ,  C07D471/14 ,  A61P35/00 ,  A61P25/28 ,  A61P19/02 ,  A61P19/08 ,  A61P31/10 ,  A61P31/12 ,  A61P17/06 ,  A61P27/06

CPC分类号： A61K31/5377 ,  A61K31/415 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  C07D401/14 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D519/00

摘要： Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:

摘要翻译： 本文提供了式I化合物及其药学上可接受的盐和包含其的组合物，用于各种方法，包括治疗诸如结肠癌，卵巢癌，胰腺癌，乳腺癌，肝癌，前列腺癌和血液学癌症的癌症：

公开(公告)号：EP3215511A4

公开(公告)日：2018-02-28

申请号：EP15857508

申请日：2015-11-06

申请人： LYSOSOMAL THERAPEUTICS INC

发明人： SKERLJ RENATO T ,  LANSBURY PETER T ,  GOOD ANDREW C ,  BOURQUE ELYSE MARIE JOSÉE

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P3/10 ,  A61P13/12 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/06 ,  A61P43/00

CPC分类号： C07D487/04 ,  A61K31/519

摘要： The invention provides substituted pyrazolol1,5-alpyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo111,5-alpyrimidine compounds described herein include 5,7-dimethyl-N-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide compounds and variants thereof.

公开(公告)号：EP1753434B2

公开(公告)日：2017-12-27

申请号：EP06738208.5

申请日：2006-03-14

申请人： ALLERGAN, INC.

发明人： CHANG, Chin-ming ,  CHANG, James, N. ,  SCHIFFMAN, Rhett, M. ,  JORDAN, R., Scott ,  CHANG-LIN, Joan-En

IPC分类号： A61K31/5575 ,  A61K9/00 ,  A61K47/18 ,  A61P27/06

CPC分类号： A61K31/5575 ,  A01N33/12 ,  A61K9/0048 ,  A61K31/14 ,  A61K31/165 ,  A61K31/557 ,  A61K47/02 ,  A61K47/12

摘要： A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.